METTL14 Antibody

Technical Parameters:

Recommended Dilutions:

• Western Blot: 1:2,000–1:14,000 (Proteintech 80790-1-RR) to 1:200–1:2,500 (Sigma-Aldrich HPA038002)

• Immunohistochemistry: 1:100–1:4,000

Molecular Weight:

• Calculated: 52 kDa

• Observed: 55–65 kDa (post-translational modifications)

Epitope Conservation:

• Cross-reactivity confirmed in primates (monkey) and rodents (mouse/rat)

Prostate Cancer (PCa):

• METTL14 overexpression correlates with poor prognosis in PCa patients

• Mechanism: Downregulates THBS1 via m6A-YTHDF2-mediated mRNA decay, promoting tumor proliferation

• In Vivo Evidence: METTL14 knockdown reduces xenograft tumor volume by 58% (DU145 cells)

Immunoregulation

• Maintains Treg cell suppressive function in transplantation models

• Key Finding: METTL14 knockdown reduces Treg-mediated inhibition of CD4+ naïve T cell proliferation by 42%

Application-Specific Validation:

Quality Control:

• Batch Consistency: ≤15% inter-lot variability (Proteintech)

• Storage Stability: 12 months at -20°C in 50% glycerol

Research Limitations and Considerations

1. Species Specificity: Most antibodies show limited reactivity beyond mammals (e.g., chicken reactivity unconfirmed in functional assays)

2. Post-Translational Effects: Observed molecular weight discrepancies suggest phosphorylation or ubiquitination impacts detection

3. Context-Dependent Expression: METTL14 exhibits tissue-specific roles (oncogenic in PCa vs. tumor-suppressive in AML) requiring model-specific validation

Emerging Therapeutic Potential

• Targetability: Small-molecule inhibitors against METTL14-methyltransferase domain show 63% tumor growth inhibition in preclinical models

• Diagnostic Utility: IHC-based METTL14 scoring stratifies PCa patients into high/low-risk groups (AUC = 0.81)